Introduction
Metastatic melanoma remains an aggressive malignancy with a poor clinical prognosis (1) . Targeted therapies show increasing promise (2, 3) , and immune based therapies -IL-2, CTLA-4 blockade, adoptive cell therapyproduce durable complete responses but only in a small percentage of patients (4) . Adoptive cell transfer (ACT) of genetically engineered autologous T cells encoding high affinity TCRα/β  chains for various melanoma TAAs including MART-1, NY-ESO-1 and gp-100 are being studied clinically (5) (6) (7) . Despite dense infiltration of metastatic lesions by tumor-reactive CTLs, the clinical efficacy of this approach, while generally improved, is still limited. The acquisition of various resistance/survival mechanisms by tumors in the setting of an otherwise specific and robust anti-tumor immune response may be one limiting factor.
Various mechanisms have been implicated in tumor recurrence or resistance following ACT. These include effector cell exhaustion (8) and development of functional tolerance (9) , down-regulation of molecules associated with Ag processing and presentation (10) , qualitative (mutations) (11) or quantitative (complete loss) (12) changes of antigenic epitope. Most ACT strategies seek to achieve a robust and long-lived immune response. Given that the immune system kills tumor cells by apoptosis, a more fundamental property of tumors that may limit the effectiveness of immunotherapy -resistance to apoptosis -may also be a dominant mechanism. Several major survival pathways -ERK1/2 MAPK, PI-3/AKT, NF-κB -are frequently deregulated in melanoma enhancing the expression of Bcl-2, Bfl-1/A1, Mcl-1, Bcl-xL that confer apoptosis-resistance.
Hence, their inhibition can potentiate melanoma sensitivity to apoptotic-stimuli (13) (14) (15) .
Bortezomib (Velcade, PS-341) is the first FDA-approved proteasome inhibitor for cancer treatment. In addition to its well-established clinical efficacy in multiple myeloma (16) and mantle cell lymphoma (17) , its use has been extended to other cancers (18) . As single agent, bortezomib is ineffective in metastatic melanoma (19) .
Through various mechanisms, mainly inhibition of NF-κB (20) and apoptosis-resistance proteins (21) (22) (23) (24) (25) , combined with other agents (26, 27) , bortezomib is effective against melanoma in vivo and in vitro. It also sensitizes melanoma cells to specific CTL attack via modulation of apoptotic machinery (28, 29) . Given the constitutive activation of NF-κB and high expression of anti-apoptotic Bcl-2 members in melanoma and the ability of bortezomib to negatively regulate these survival mechanisms (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) , the efficacy of boretzomib in combination with immunotherapy in the treatment of metastatic melanoma warrants further evaluation.
We have recently reported the establishment of MART TCR-engineered (F5 CTL)-resistant (R) melanoma
clones from several MART-1 + /A*0201 + lines. When compared to parental cells, R lines expressed comparable levels of surface MART-1/A*0201 complex, but were resistant to F5 CTL. Targeted therapy using pharmacological inhibitors of NF-κB pathway (bortezomib, Bay11-7085, siRNA) sensitized these resistant cell lines to F5 CTL cytotoxicity (29) . Other groups have reported alterations in gene expression and cell signaling dynamics, which account for resistance to specific CTL-killing, whereby targeting the aberrant pathways or apoptotic proteins can overcome resistance (30) (31) (32) 
Materials and Methods
Cell lines. M244 human melanoma cell line was established as described (33) . For the generation of M244R lines, parental (P) cells were grown in the presence of step-wise increasing numbers of F5 CTLs (E:T 20:1, 40:1, 60:1) for a total of 4 weeks. 30-40% of cells survived the first selection cycle (20:1); their percentage drastically reduced during subsequent cycles until no further killing was observed. Remaining viable cells were subjected to limiting dilution analysis. Single cells were propagated, maintained in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) in excess (10:1) F5 CTLs, but were grown in F5 CTL-free medium at least one week prior to analysis (29) . Cultures were incubated in controlled atmosphere at 37 o C with saturated humidity at 0.5×10 6 cells/ml and were used at 50-70% confluency for all assays. Cell cultures were routinely authenticated and assayed for mycoplasma contamination.
Reagents. Phospho-IκB-α, p-IKKα/β and p-ERK1/2 Abs were obtained from Imgenex (San Diego, CA), and
Cell Signaling (Beverley, MA), respectively. Other Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Bortezomib was diluted in DMSO. DMSO concentration did not exceed 0.1% in any experiment.
Transduction of CD8
+ CTLs with F5 MART-1 TCRα/β retrovirus. Non-adherent population of healthy donor human PBMCs were cultured in AIM-V media supplemented with 5% human AB serum, αCD3 Ab (50ng/ml) and IL-2 (300IU/ml) for 48hr. CD3 + CD8 + CTLs were isolated by EasyStep Negative Selection enrichment kits (Stem Cell Technologies) according to manufacturer's instructions. CTLs were transduced with MSCV-MART-1 TCR as described (5) (6) (7) 29) . CD8 + CTLs with >95% MART-1 TCRα/β expression were used in all experiments.
Cytotoxicity assay. Melanoma cultures were trypsinized for 5min, washed once in cold PBS and labeled with 100µCi of Na 2
51
CrO 4 for 1hr (37°C/5%CO 2 ). After 3X washes, 10 4 cells were added to V-bottom 96-well plates and used immediately as described (29) . Percentage of specific 51
Cr-release was measured as: % Cytotoxicity = (experimental release-spontaneous release) / (total release-spontaneous release) x 100. /ml cells (in serum-free medium) were pulsed with MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (ELAGIGI LTV) peptide (10μg/ml-1hr) at room temperature as described (34) . Cells were then plated in 10cm petri-dishes at 0.5X10 5 /ml in complete medium and used in assays as described in the text.
NF-κB transcription activity and cytokine release. Transcriptional activity of nuclear p65 and cytokine release were measured using TransAM (Active Motif, Carlsbad, CA) and ELISA assay kits (eBiosciences, San Deigo, CA), respectively, according to manufacturer's instructions. Quantitative real-time PCR (qPCR). Samples were analyzed in triplicate with iQ SYBR Green Supermix using iCycler Sequence Detection System (BioRad) as described (29 Fig. S5, 6 ). These results suggest that M244R lines express higher levels of NF-κB-dependent anti-apoptotic factors, which renders them resistant to F5 CTL-killing and bortezomib can reduce their expression levels. These results also suggest that MART-1 restoration is NF-κB-independent as Bay11-7085 was unable to restore MART-1 expression ( Figure 4B ).
We next examined the regulation of additional survival pathways by bortezomib. We noted that M244R1 and M244R2 lines express relatively high levels of pERK1/2 and low levels of pJNK1/2. Bortezomib treatment reduced pERK1/2 levels (similar to specific ERK1/2 inhibitor PD098059) (35) while increasing pJNK1/2 concomitant with increased MART-1 levels ( Figure 4C ). While inhibition of ERK1/2 pathway restored recognition of M244R1 line ( Figure 4D) , it was insufficient to sensitize the M244R1 line to F5 CTL ( Figure 4D ).
Bortezomib (± PD098059) efficiently sensitized M244R1 to F5 CTL-killing ( Figure 4E ). enhancing the expression of Bcl-2, Bfl-1/A1, Mcl-1, Bcl-xL , play a key role in determining melanoma response to apoptotic stimuli including CTLs (28, 29, 39, 40) . Further support for the involvement of acquired or inherent properties of tumors in immunotherapy resistance was shown by melanoma progression despite the presence of significant numbers of antigen-specific CTLs in vivo (41) . Biochemical analysis revealed constitutive activation of the NF-κB pathway and over-expression of anti-apoptotic Bcl-2, Bcl-xL and Mcl-1 in the R lines.
Using specific inhibitors (Bay11-7085, 2MAM-A3; Figure 6 ) or specific gene silencing of resistance factors, we show that pharmacological inhibition of NF-κB or Bcl-2 members alone is inadequate to render the M244R lines recognizable by F5 CTLs or reverse their resistance. However, combining these strategies with MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide loading reversed the resistance. These results plus the inability of Bay11-7085 to induce MART-1, suggest that MART-1 re-expression is independent of NF-κB activation status. However, brief pretreatment 
